A Phase III Trial of HRS-1893 in Patients With Obstructive Hypertrophic Cardiomyopathy

Sponsor
Shandong Suncadia Medicine Co., Ltd.
Study ID
NCT07021976
Phase
PHASE3
Status
Recruiting
Apply to this trial

Conditions

  • Obstructive Hypertrophic Cardiomyopathy

Eligibility Criteria

Sex
ALL
Age
18 Years - 85 Years
Healthy Volunteers
Not accepted

Interventions

  • HRS-1893 Tablets — DRUG
    HRS-1893 tablets.
  • HRS-1893 Placebo Tablets — DRUG
    HRS-1893 placebo tablets.

Study Details

The study is being conducted to evaluate the efficacy and safety of HRS-1893 for obstructive hypertrophic cardiomyopathy.

Key Dates

Start date
Aug 11, 2025
Status verified
Aug 2025
Primary completion
Sep 30, 2026
Completion
Nov 30, 2026

Study Design

Enrollment
216 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: HRS-1893 Group
  • Placebo Comparator: HRS-1893 Placebo Group

Primary Outcome Measure

The clinical response rate of treatment with HRS-1893. [ Time Frame: After 24 weeks of HRS-1893 treatment. ]

Central Contacts

Related Studies